Literature DB >> 11994376

Serum and tissue expression of activin a in postmenopausal women with breast cancer.

Fernando M Reis1, Luigi Cobellis, Lilian C Tameirão, Gabriele Anania, Stefano Luisi, Ilma S B Silva, Walter Gioffrè, Anna M Di Blasio, Felice Petraglia.   

Abstract

Activins are growth factors involved in the control of cell proliferation and differentiation. Human breast tissues express immunoreactive activin subunits, and activin A is able to inhibit the replication of mammary cells in vitro. The aim of the present study was to evaluate 1) whether breast cancer expresses activin betaA subunit mRNA, 2) whether serum activin A levels are altered in postmenopausal women with breast cancer, and 3) how circulating activin A levels change after tumor removal. Four groups of women (n = 158) were enrolled for the present prospective study: two groups were composed of postmenopausal women with breast cancer (n = 74) or benign lesions (n = 15); the third was a control group composed of healthy postmenopausal women (n = 62); and the fourth group included healthy fertile women (n = 7) undergoing plastic surgery with removal of non-neoplastic mammary tissue. RT-PCR showed that betaA subunit mRNA was expressed in breast carcinoma, fibroadenoma, and normal mammary tissue, and the level of expression was higher in carcinoma than in normal tissue (P < 0.05). Dimeric activin A was detectable in homogenates of breast cancer tissue at concentrations twice as high as in non-neoplastic tissue (P < 0.01). In women with breast cancer, median serum activin A levels were significantly higher than in controls (P < 0.001). The high serum activin A levels in patients with breast cancer were not correlated with the presence of lymph node metastasis, tumor grade, or tumor diameter. After tumor excision, a significant decrease of activin A in the first and second postoperative days was observed (P < 0.01; Friedman's ANOVA). Conversely, activin A levels remained unchanged after plastic surgery in healthy women. The present results suggest that activin A is expressed and secreted in postmenopausal women with breast cancer. The pathophysiological and possible clinical implications of this finding remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994376     DOI: 10.1210/jcem.87.5.8512

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

Review 1.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 3.  Cancer-targeted therapies and radiopharmaceuticals.

Authors:  Tilman D Rachner; Franz Jakob; Lorenz C Hofbauer
Journal:  Bonekey Rep       Date:  2015-06-03

Review 4.  The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Authors:  Darcie D Seachrist; Ruth A Keri
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

5.  Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

Authors:  Gaetano Leto; Lorena Incorvaia; Giuseppe Badalamenti; Francesca M Tumminello; Nicola Gebbia; Carla Flandina; Marilena Crescimanno; Giovambattista Rini
Journal:  Clin Exp Metastasis       Date:  2006-07-14       Impact factor: 5.150

6.  BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo.

Authors:  Michael R Shurin; Yang Ma; Anton A Keskinov; Ruijing Zhao; Anna Lokshin; Marianna Agassandian; Galina V Shurin
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

7.  Overexpression of CD36 in mammary fibroblasts suppresses colony growth in breast cancer cell lines.

Authors:  Qingsu Cheng; Kosar Jabbari; Garrett Winkelmaier; Cody Andersen; Paul Yaswen; Mina Khoshdeli; Bahram Parvin
Journal:  Biochem Biophys Res Commun       Date:  2020-03-16       Impact factor: 3.575

8.  The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.

Authors:  Caroline Wilson; Penelope Ottewell; Robert E Coleman; Ingunn Holen
Journal:  BMC Cancer       Date:  2015-02-14       Impact factor: 4.430

9.  Translational regulation of inhibin βA by TGFβ via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells.

Authors:  B V Howley; G S Hussey; L A Link; P H Howe
Journal:  Oncogene       Date:  2015-06-22       Impact factor: 9.867

10.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.